Hepion Pharmaceuticals, Inc. (HEPA): Net earnings per share for the last 12 months

Symbol and logo of brand Hepion Pharma (HEPA)

Hepion Pharmaceuticals strictly adheres to environmental regulations regarding chemical disposal in its laboratories. Meanwhile, geopolitical instability complicates patent protection and global supplies, as clearly demonstrated by the annual net income per share chart, where the figure stood at -82.03. Business development is based on the strategic outsourcing of clinical trials for liver drugs through external contractors.

HEPA (Hepion Pharmaceuticals) Net earnings per one share for the last twelve months history from 07/04/2022 to 06/14/2025

Analytical breakdowns for Hepion Pharma (HEPA)

- stock exchange capitalization data:
Manufactured products of Hepion Pharmaceuticals Inc.

Analyzing the rolling earnings per share trend, we see the current state of the biotech issuer Hepion Pharmaceuticals (HEPA). This indicator reflects the net income remainder distributed across the total volume of issued securities for the year. The metric is sensitive to operating losses and the volume of equity capital. For a company in the liquidation stage following failed clinical trials, this figure captures the cash burn rate. The negative trend confirms a critical crisis in the business model.